Supernus Pharmaceuticals
SUPN
288 hedge funds and large institutions have $2.6B invested in Supernus Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 95 increasing their positions, 113 reducing their positions, and 60 closing their positions.
4.46% less ownership
Funds ownership: 103.53% → 99.07% (-4.5%)
10% less funds holding
Funds holding: 320 → 288 (-32)
16% less repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 113
19% less capital invested
Capital invested by funds: $3.21B → $2.6B (-$603M)
29% less call options, than puts
Call options by funds: $13M | Put options by funds: $18.2M
50% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 60
71% less funds holding in top 10
Funds holding in top 10: 7 → 2 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$70.6M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$28.1M |
| 3 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$16.8M |
| 4 |
BlackRock
New York
|
+$15.4M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$48.3M |
| 2 |
CRCP
Copper Rock Capital Partners
Boston,
Massachusetts
|
-$29.3M |
| 3 |
PCM
Penserra Capital Management
Orinda,
California
|
-$29M |
| 4 |
Renaissance Technologies
New York
|
-$20.6M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$14.9M |
SUPN Hedge Fund Activity: Q3 2018 in Review
288 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q3 2018, worth a combined $2.6B — down 19% from $3.21B a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of SUPN and 30 opened new positions — a net loss of 30 holders — while 113 trimmed existing stakes and 95 added.
The largest buyer was Fidelity Investments, adding an estimated $70.6M. The largest seller was 1832 Asset Management, exiting entirely with an estimated $48.3M sold.
- 288 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q3 2018, down from 320 in Q2 2018.
- Funds reported $2.6B of Supernus Pharmaceuticals stock for Q3 2018, down 19% quarter-over-quarter.
- 30 funds opened new Supernus Pharmaceuticals positions in Q3 2018 and 60 closed out, a net change of -30 holders.
- The largest Supernus Pharmaceuticals buyer in Q3 2018 was Fidelity Investments, an estimated $70.6M added.
- The largest Supernus Pharmaceuticals seller in Q3 2018 was 1832 Asset Management, an estimated $48.3M sold.
Based on aggregated 13F filings for Q3 2018.